The McCourt Foundation’s Neurological Symposium
The 2026 Neurological Symposium returns Saturday, October 3, at the Marriott Boston Quincy Hotel, bringing together the community for a day of expert insight into neurological health. The morning session, beginning at 10am EST, will focus on Multiple Sclerosis, followed by a 12pm EST session on Alzheimer's disease. Speakers and topics will be announced soon. Both sessions will be livestreamed and recorded, so attendees can join in person or watch from anywhere, live or on their own schedule.
Best of all, the symposium is completely free to attend, with free on-site parking available for all guests. Registration opens mid-August 2026, so stay tuned for details on how to reserve your spot.
2025 Sessions
Thank you to everyone who attended last years symposium to hear the about the latest research, cures and treatments for neurological diseases! We had participants join us live and virtually, representing 6 countries, 17 states, and 137 towns and cities. Stay tuned for future updates on next years Neurological Symposium.
View in-depth video recordings featuring renowned experts from the 2025 Neurological Symposium as they delve into cutting-edge research on cures and treatments for neurological diseases.
Rebecca Gillani, MD, PhD - Massachusetts General Hospital
Topic: Redefining Multiple Sclerosis Progression
Jonathan Zurawski, MD - Brigham & Women’s Hospital
Topic: New Advances in Progressive MS
Nancy Sicotte, MD - Cedars-Sinai
Topic: New biomarkers and treatments for progressive MS
Valentina Perosa, MD, PhD - Neurology, Mass General Research Institute
Topic: Healthy Vessels, Healthy Brain: what can you do against dementia’
John Dickson, MD, PhD - Massachusetts General Hospital
Topic: Real-world clinical experience with anti-amyloid therapy for the treatment of Alzheimer's disease
Michael Schwarzschild, MD, PhD - Massachusetts General Hospital
Topic: Advances toward the Prevention of Parkinson’s Disease
Vikram Khurana, MD, PhD - Brigham & Women’s Hospital
Topic: My Trial: Parkinson’s disease, Stem Cells and the Advent of Precision Clinical Trials

